DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Glaucoma" report has been added to Research and Markets' offering.
This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Topics Covered:
1 KEY TAKEAWAYS
2 DISEASE BACKGROUND
- Subtypes
3 TREATMENT
- Eye drops
- Oral medications
4 EPIDEMIOLOGY
5 PIPELINE DRUGS
6 MARKETED DRUGS
- Approvals by country
7 KEY UPCOMING EVENTS
8 KEY REGULATORY EVENTS
- Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test
- MIXiii Biomed 2017: Aging, Technology & Robotics In The Digital World
- Bausch & Lomb/Nicox Eye Drug Resubmission Is Assigned August Review Goal
- Aerie's Rhopressa Lands At FDA Again
- FDA Seeks Plant Clean-Up Before Approving Eye Drug
- Aerie Grounds Rhopressa
- Regeneron Partnering With Ocular May Provide Needed Tech Validation
- New Combinations
- US Approvals Analysis
9 LICENSING AND ASSET ACQUISITION DEALS
- Santen, TwoXAR Collaborate In Ophthalmics
- Otsuka/Acucela (No Deal)
- Alcon Puts Money Where Mouth Is With Glaucoma Device Buy
10 PARENT PATENTS
11 REVENUE OPPORTUNITY
12 CLINICAL TRIAL LANDSCAPE
- Sponsors by status
- Sponsors by phase
- Recent events
13 BIBLIOGRAPHY
For more information about this report visit https://www.researchandmarkets.com/research/29vkml/market_spotlight
